| Family Health Center Of Benicia | |
|
1440 Military W Benicia CA 94510-2451 | |
| (707) 745-0711 | |
| (707) 745-0788 |
| Full Name | Family Health Center Of Benicia |
|---|---|
| Speciality | Family Medicine |
| Location | 1440 Military W, Benicia, California |
| Authorized Official Name and Position | Nanette C Bennett (OFFICE MANAGER) |
| Authorized Official Contact | 7077450711 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Family Health Center Of Benicia 1440 Military W Benicia CA 94510-2446 Ph: (707) 745-0711 | Family Health Center Of Benicia 1440 Military W Benicia CA 94510-2451 Ph: (707) 745-0711 |
| NPI Number | 1336194646 |
|---|---|
| Provider Enumeration Date | 05/24/2006 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 2860403474 |
|---|---|
| Medicare Enrollment ID | O20060510000630 |
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336194646 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Shelly Maramonte |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205895695 PECOS PAC ID: 5597851105 Enrollment ID: I20071012000186 |
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
| Provider Name | Laura J Dalton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376502898 PECOS PAC ID: 2769578384 Enrollment ID: I20071012000214 |
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
| Provider Name | Zita Latona |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528270998 PECOS PAC ID: 1254421068 Enrollment ID: I20071217000840 |
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
| Provider Name | Kristina J Kim |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1194993923 PECOS PAC ID: 5991739344 Enrollment ID: I20080617000192 |
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
| Provider Name | Aaron Joseph Zaks |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447600317 PECOS PAC ID: 8123361334 Enrollment ID: I20190509002173 |
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
News Archive
In an historic court case, Judge Jackson at the High Court in London ruled that the mother of a 14-year-old girl could carry out the girl's wish to be cryogenically preserved after her death, despite objections from the girl's estranged father.
Veloxis Pharmaceuticals A/S today announced that it has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Spectranetics Corporation has announced it has received clearance from the Food and Drug Administration (FDA) to market its TURBO elite line of laser catheters for the treatment of all stenoses and occlusions within arteries of the leg.
› Verified 8 days ago
Peter Navolanic M.d. Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1100 Rose Dr, Suite 140, Benicia, CA 94510 Phone: 707-751-1567 Fax: 707-745-1902 | |
Family Doctor Medical Group Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 160 E N St, Benicia, CA 94510 Phone: 707-745-9211 Fax: 707-745-3015 | |
Solano Family Physicians Medical Group Prof Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1100 Rose Dr, Suite 140, Benicia, CA 94510 Phone: 707-745-2705 Fax: 707-745-1902 |